Jornay PM vs. Vyvanse: What's the Difference?
Jornay PM and Vyvanse are both medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD), but they differ in their formulation, mechanism of action, and dosing schedule.
How Do Jornay PM and Vyvanse Work?
Vyvanse (lisdexamfetamine dimesylate) is a prodrug that is converted to dextroamphetamine in the body [1]. Dextroamphetamine is a central nervous system stimulant that increases levels of dopamine and norepinephrine in the brain, which are thought to be deficient in individuals with ADHD [2].
Jornay PM, also a stimulant medication, uses a novelomethylphenidate delivery system. It is designed to release medication in two distinct phases: an initial release in the morning and a second release approximately 10-12 hours later [3]. This dual-release mechanism aims to provide extended symptom control throughout the day and into the evening [3]. The exact mechanism of Jornay PM's dual-release system, while based on methylphenidate, is distinct from standard methylphenidate formulations [3].
When Does the Medication Start Working and How Long Does It Last?
Vyvanse typically starts working within 1 to 2 hours after taking it, and its effects can last for up to 14 hours [4].
Jornay PM's dual-release system is intended to provide symptom coverage throughout the day and into the evening, addressing the potential need for medication to last longer for some individuals [3]. The initial release provides morning coverage, and the later release is designed to extend coverage through the evening hours.
What Are the Potential Side Effects?
Common side effects for both Jornay PM and Vyvanse can include decreased appetite, dry mouth, insomnia, and weight loss [1, 3]. Other potential side effects for Vyvanse may include increased blood pressure, rapid heart rate, and dizziness [1]. Jornay PM may also cause anxiety, irritability, and stomach upset [3]. Serious side effects for both medications can include cardiovascular problems, psychiatric issues, and a risk of abuse and dependence [1, 3].
Are There Different Dosages Available?
Vyvanse is available in various capsule strengths, allowing for dose titration to meet individual needs [1]. Jornay PM is also available in different dosage strengths, with the dosage adjusted based on the individual's response and tolerance [3].
How Do the Costs Compare?
The cost of both Jornay PM and Vyvanse can vary significantly based on insurance coverage, pharmacy, and dosage. Neither medication is typically covered by Medicare Part D at the lowest tier [5]. Information on the specific cost comparison for both medications can be found on drug information websites like DrugPatentWatch.com [6].
What Are the Patent and Exclusivity Details?
Information regarding the patents and exclusivity periods for both Jornay PM and Vyvanse can be accessed through resources such as DrugPatentWatch.com, which tracks patent expiration and market exclusivity for pharmaceutical products [6].
What Are Other Treatment Options for ADHD?
Beyond Jornay PM and Vyvanse, other ADHD medications include immediate-release and extended-release formulations of methylphenidate (e.g., Ritalin, Concerta) and amphetamine salts (e.g., Adderall) [7]. Non-stimulant medications, such as atomoxetine (Strattera) and guanfacine (Intuniv), are also available [7]. Behavioral therapies are also a common component of ADHD treatment [7].
---
Sources
[1] Vyvanse (lisdexamfetamine dimesylate) Capsules. (n.d.). RxList. Retrieved from https://www.rxlist.com/vyvanse-drug.htm
[2] Lisdexamfetamine. (n.d.). National Institute on Drug Abuse. Retrieved from https://www.drugabuse.gov/publications/drugfacts/lisdexamfetamine
[3] Jornay PM. (n.d.). Jornay PM Official Website. Retrieved from https://www.jornaypm.com/
[4] Vyvanse for ADHD. (n.d.). Vyvanse Official Website. Retrieved from https://www.vyvanse.com/
[5] Medicare Part D Coverage for ADHD Medications. (n.d.). Medicare.gov. Retrieved from https://www.medicare.gov/
[6] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[7] Attention-Deficit/Hyperactivity Disorder (ADHD). (n.d.). Mayo Clinic. Retrieved from https://www.mayoclinic.org/diseases-conditions/adhd/diagnosis-treatment/drc-20350894